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Abstract. Pancreatic ductal adenocarcinoma (PDA) 
remains one of the most difficult to treat of all malignancies. 
Multimodality regimens provide only short-term symptomatic 
improvement with minor impact on survival, underscoring the 
urgent need for novel therapeutics and treatment strategies for 
PDA. Trichothecenes are powerful mycotoxins that inhibit 
protein synthesis and induce ribotoxic stress response in 
mammalian cells. Verrucarin A (VC-A) is a Type D macrocy-
clic mycotoxin which inhibited cell proliferation and induced 
apoptosis in breast cancer cells. However, the antitumor 
activity of VC-A for PDA cells has not been investigated. 
Here we show potent antitumor activity and the mechanism of 
action of VC-A in PDA cell lines. VC-A strongly inhibited the 
proliferation and arrested cells in the S phase of the cell cycle. 
The blocking of cell cycle progression by VC-A was associated 
with the inhibition of cell cycle regulatory proteins cyclin D1, 
cyclin E, cyclin-dependent kinases (cdks) cdk2, cdk4 and 
cdk inhibitor WAF1/21. VC-A induced apoptosis in PDA 
cells as indicated by the increased Annexin V FITC-binding, 
cleavage of poly(ADP-ribose) polymerase-1 (PARP-1) and 
procaspases-3, -8 and -9. VC-A also induced mitochondrial 
depolarization and release of cytochrome c and it inhibited 
Bcl-2 family proteins that regulate apoptosis (Bcl-2, Bcl-xL, 
Bax and Bad). In addition, VC-A reduced the levels of 
inhibitors of apoptosis survivin and c-IAP-2. Finally, VC-A 
downregulated the expression of prosurvival phospho-Akt 
(p-Akt), nuclear factor κB (NF-κB) (p65) and mammalian 
target of rapamycin (p-mTOR) signaling proteins and their 
downstream mediators. Together, these results demonstrated 
strong antiproliferative and apoptosis-inducing activity of 
verrucarin A for PDA cells through cell cycle arrest and inhi-
bition of the prosurvival (antiapoptotic) AKT/NF-κB/mTOR 
signaling.
Introduction
Pancreatic ductal adenocarcinoma (PDA) is almost uniformly 
lethal with an estimated annual number of 45,220 new cases 
approximating 38,460 annual deaths and a 5-year survival 
rate of <5% (1-3). Late initial diagnosis, aggressive meta-
static behavior and resistance to chemoradiotherapy render 
pancreatic cancer one of the most difficult to treat of all malig-
nancies. Surgical resection is potentially curative in a minority 
of patients; however, >80% of the patients are diagnosed with 
locally advanced disease that precludes surgical intervention. 
Systemic gemcitabine alone or in combination with 5-FU, 
irinotecan and oxaliplatin (FOLFIRINOX) is the current 
standard of care for advanced pancreatic cancer, providing 
short-term symptomatic improvement with minor impact on 
survival (4-6). Thus, there is an urgent need for developing 
novel agents for the treatment of pancreatic cancer.
Trichothecenes are structurally related low molecular 
weight sequiterpenoid metabolites produced by filamentous 
fungi, such as Myrothecium, Stachybotrys, Fusarium and 
others (7). Trichothecenes are potent mycotoxins that are 
believed to be responsible for adverse respiratory and neuro-
logical effects of damp and moldy indoor environments (8-10). 
They elicit a wide range of biological responses in eukaryotic 
cells, including inhibition of protein synthesis and cell prolif-
eration; induction of cytotoxicity, ribotoxic stress responses 
and modulation of immune responses (11-16). Verrucarin A 
(VC-A) is a macrocyclic trichothecene that evokes strong 
antiproliferative and proapoptotic responses in cancer cells 
(17-20). There is some evidence that the antiproliferative and 
apoptosis-inducing effects of VC-A are due to the inhibition 
of protein synthesis through blocking of peptidyl transferase 
activity and activation of c-jun N-terminal kinase (c-JNK) and 
p-38 MAP kinase (14,17,18).
In a previous report, VC-A was identified as a major 
mediator of the anticancer activity in salt water cultures of 
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Myrothecium verrucaria isolated from a sponge species 
collected in Hawaii (21). However, the mode of cell death 
or the mechanism by which VC-A kills tumor cells was not 
investigated in that study.
In this study, we investigated the anticancer activity of 
verrucarin A against PDA cell lines. Data showed that VC-A 
inhibits the proliferation and induces cell cycle arrest in 
S phase by inhibiting cell cycle-related regulatory proteins. 
VC-A induced apoptosis in PDA cells through the activation 
of procaspases, induction of mitochondrial depolarization and 
inhibition of Bcl-2 and IAP family of proteins that regulate 
apoptosis. In addition, VC-A also inhibited prosurvival 
signaling proteins (e.g., p-Akt, NF-кB and p-mTOR) and their 
downstream mediators.
Materials and methods
Reagents. Verrucarin A isolated from salt water cultures of 
Myrothecium verrucaria separated from Spongia Sp. was 
obtained from Dr Phillip Crews, University of California, 
Santa Cruz. Anti-caspase-3, caspase-8, and caspase-9 anti-
bodies were purchased from BD Pharmingen (San Diego, CA, 
USA). Antibodies against p-Akt (ser473), p-mTOR (Ser2448), 
PARP-1, anti-NF-κB (p65), anti-Bcl-2, anti-Bcl-xL, anti-Bax, 
anti-Bak, anti-Bad and β-actin were purchased from Santa 
Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). Anti-cdk2, 
cdk4, cdk6, anti-cyclin D, anti-cyclin E and anti-p21 anti-
bodies were from Cell Signaling Technology (Boston, MA, 
USA). 96 AQueous One Solution Proliferation assay system 
was from Promega (Madison, WI, USA). Stock solution of 
VC-A (2 mM) was prepared in DMSO and all test concentra-
tions were prepared by diluting stock solution in tissue culture 
medium.
Cell lines. MiaPaCa-2, Panc-1 and BxPC-3 PDA cell lines were 
obtained from the American Type Culture Collection (ATCC, 
Rockville, MD, USA). MiaPaCa-2 and Panc-1 cell lines were 
grown in DMEM tissue culture medium whereas BxPC-3 cells 
were cultured in RPMI-16 (Gibco BRL, Rockville, MD, USA) 
supplemented with 10% fetal bovine serum, 1% penicillin/
streptomycin, and 25 mM HEPES buffer. Cells were incubated 
at 37˚C in a humidified atmosphere consisting of 5% CO2, 
95% air and maintained by splitting cultures twice a week.
MTS assay. Tumor cells (1x104) in 100 µl of tissue culture 
medium were seeded into each well of a 96-well plate. After 
24-h incubation to allow cells to adhere, cells were treated 
with VC-A at concentrations ranging from 0 to 0.625 µM. 
Cultures were incubated for additional 72 h and cell viability 
was then determined by the colorimetric MTS assay using 
CellTiter 96 AQueous One Solution Proliferation assay system 
from Promega (Madison), which measures the bioreduction 
of tetrazolium compound MTS in the presence of electron-
coupling reagent phenazine methosulfate. The absorbance, 
which is directly proportional to the number of viable cells in 
the cultures, was measured at 490 nm using a microplate reader.
Cell cycle analysis. The distribution of cells in various cell 
cycle phases was analyzed by measuring cellular DNA content. 
Untreated (control) (2x106) or VC-A-treated cells were fixed in 
70% ethanol overnight at 4˚C. Cells were washed twice and 
resuspended in 0.8 ml of PBS. To each tube, 100 µl of DNAse 
free RNAse (500 µg/ml) and 100 µl of propidium iodide 
(500 µg/ml) was added and tubes were incubated at room 
temperature in the dark for 30 min. Cellular DNA content was 
determined by flow cytometry using Accuri C6 flow cytometer 
(Accuri Cytometers Inc. Ann Arbor, MI, USA).
Annexin V-FITC binding. Induction of apoptosis was assessed 
by the binding of Annexin V to phosphatidylserine, which is 
externalized to the outer leaflet of the plasma membrane early 
during apoptosis. Briefly, MiaPaCa-2 and BxPC-3 cells treated 
with VC-A (0-0.625 µM) for 24 h were resuspended in the 
binding buffer provided in Annexin V-FITC apoptosis detec-
tion kit II (BD Biosciences, Pharmingen). Cells were mixed 
with 5 µl of Annexin V-FITC reagent, 5 µl of PI, and incubated 
for 30 min at room temperature in the dark. Stained cells were 
analyzed by flow cytometry.
Mitochondrial depolarization assay. Alteration in mitochon-
drial potential by VC-A was determined using mitochondrial 
potential sensor dye JC-1 (Molecular Probes, Invitrogen, 
San Diego, CA, USA). Briefly, 1x106 control (untreated) and 
VC-A- treated cells in 1 ml culture medium were loaded with 
JC-1 (10 µg/ml) for 10 min at 22˚C and analyzed by flow 
cytometry. In normal cells, dye is aggregated in mitochon-
dria, fluoresces red, and is detected in the FL2 channel. In 
cells with altered mitochondrial potential, the dye fails to 
accumulate in the mitochondria, remains as monomers in 
the cytoplasm, fluoresces green, and is detected in the FL1 
channel.
Western blotting. Cell lysates were prepared by detergent 
lysis [1% Triton-X 100 (v/v), 10 mM Tris-HCl (pH 7.5), 5 mM 
EDTA, 150 mM NaCl, 10% glycerol, 2 mM sodium vanadate, 
5 µg/ml leupeptin, 1 µg/ml aprotinin, 1 µg/ml pepstatin A and 
10 µg/ml 4-2-aminoethyl-benzenesulfinyl fluoride]. Lysates 
were clarified by centrifugation at 14,000 x g for 10 min at 
4˚C, and protein concentrations were determined by Bradford 
assay. Samples (50 µg) were boiled in an equal volume of 
sample buffer [20% glycerol, 4% SDS, 0.2% bromophenol 
blue, 125 mM Tris-HCl (pH 7.5), and 640 mM 2-mercapto-
ethanol] and separated on 10% SDS-polyacrilamide gels. 
Proteins resolved on the gels were transferred to nitrocellulose 
membranes. Membranes were blocked with 5% milk in 10 mM 
Tris-HCl (pH 8.0), 150 mM NaCl with 0.05% Tween-20 (TPBS) 
and incubated with protein specific antibodies followed by 
HRP-conjugated secondary antibody. Immune complexes 
were visualized with enhanced chemiluminescence detection 
system from Amersham Corp. (Arlington Heights, IL, USA). 
The immunoblots were imaged and the density of protein 
bands was analyzed using Image/J software (imagej/nih.gov/
ij/download/). The protein band densities were normalized to 
the corresponding β-actin levels and presented as fraction of 
untreated control considered as 1.0.
Statistical analysis. Data are presented as means ± SD. 
The differences between control and treatment groups were 
analyzed using Student's t-test and differences with p<0.05 
were considered statistically significant.
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Results
VC-A inhibits proliferation and cell cycle progression in 
PDA cells. The effect of VC-A on proliferation of MiaPaCa-2, 
Panc-1 and BxPC-3 PDA cells was examined using the MTS 
assay. For this, cells were treated with VC-A at concentra-
tions of 0-0.625 µM for 72 h and the viability of cultures 
was determined. As shown in Fig. 1, significant reduction in 
viability was observed at the lowest concentration of 0.019 µM 
VC-A (MiaPaCa-2 = 36±1.4 SD; Panc-1 = 57±1.8 SD, p<0.05). 
BxPC-3 cultures also showed measurable reduction in viability 
at 0.019 µM VC-A (21±0.6 SD). In all three cell lines, reduc-
tion in viability significantly increased at VC-A concentrations 
of 0.039-0.625 µM (MiaPaCa-2 = 63-80% reduction; Panc-1 
= 57-78% reduction; BxPC-3 = 75-86% reduction, p<0.01). 
These data demonstrated potent antiproliferative activity of 
VC-A against PDA cells.
In a previous report, VC-A was demonstrated to be 
6-10-fold less cytotoxic to normal bone marrow cells compared 
to cancer cell lines (21). In addition, VC-A was also inactive or 
only weekly active against non-cancerous Vero cells derived 
from monkey kidney compared to cancer cell lines (12).
Verrucarin A induces cell cycle arrest and inhibits cell cycle-
related regulatory proteins in PDA cells. Since VC-A inhibited 
the proliferation of PDA cells we investigated its effect on 
cell cycle progression and cellular proteins that regulate cell 
division. For effect on cell cycle progression, MiaPaCa-2 and 
BxPC-3 cells were treated with VC-A (0-0.04 µM) for 24 h, 
stained with PI and cellular DNA content was analyzed by 
flow cytometry. Treatment with VC-A resulted in arrest of 
cells in the S cell cycle phase in both cell lines (Fig. 2A). In 
MiaPaCa-2 cells, the accumulation of cells in S phase was 
VC-A concentration-dependent (e.g., 17-27% at 0-0.04 µM 
VC-A), whereas in BxPC-3 cells all of the S-phase arrest 
occurred at 0.04 µM VC-A. To determine the effect of VC-A 
on cell cycle regulatory proteins, cell lysates of MiaPaCa-2 
and BxPC-3 cells treated with VC-A (0.078-0.625 µM) for 
24 h were analyzed for the levels of cyclin D1, cyclin E, cdk2, 
cdk4 and WAF1/21 (p21) by western blotting. As shown 
in Fig. 2B, treatment with VC-A reduced the levels of these 
proteins mostly in a concentration-dependent manner. These 
data suggested that VC-A arrests PDA cells in S cell cycle 
phase by inhibiting cell cycle regulatory proteins.
VC-A induces apoptosis in PDA cells. Whether cell cycle 
arrest leads to the induction of apoptosis was investigated 
next. Induction of apoptosis was by analyzed by the binding of 
Annexin V-FITC to cells treated with VC-A. Thus, MiaPaCa-2 
and BxPC-3 cells were treated with VC-A (0.078-0.625 µM) 
for 24 h and binding of Annexin V-FITC was determined 
by flow cytometry. As shown in Fig. 3A, only a small 
percentage of untreated MiaPaCa-2 and BxPC-3 cells bound 
Annexin V-FITC (<5%). The percentage of Annexin V-FITC 
binding MiaPaCa-2 increased from 51% at 0.078 µM to 57% 
at 0.625 VC-A (p<0.01). On the other hand, the percentage of 
Annexin V-FITC binding BxPC-3 cells increased in a dose-
dependent manner, e.g., 24, 31, 3 and 43% at 0.078, 0.15, 0.325 
and 0.625 µM VC-A.
The induction of apoptosis by VC-A was confirmed by 
the cleavage of PARP-1 and procaspases. Tumor cells were 
treated with VC-A as described above and the cleavage of 
PARP-1 and procaspases was analyzed by western blotting. As 
shown in Fig. 3B, treatment with VC-A induced the cleavage 
of native PARP-1 (110-kDa fragment) as identified by the 
emergence of an 89-kDa cleaved PARP-1 fragment in both 
cell lines. Treatment with VC-A also induced the processing 
of procaspases-3,-8 and -9 as determined from a decrease in 
native proteins (procaspases-3 and -8) or the emergence of 
the cleaved fragments (procaspase-9) (Fig. 3C). However, the 
effect of VC-A on the activity of these caspases was not deter-
mined. Together, increase in Annexin V-FITC-binding and the 
cleavage of PARP-1 and processing of procaspases-3, -8 and -9 
demonstrated induction of apoptosis in PDA cells by VC-A.
VC-A induces mitochondrial depolarization and release of 
cytochrome c. Whether mitochondrial pathway of apoptosis 
was involved in the apoptotic cell death of PDA cells by 
VC-A was examined next. As a measure of mitochondrial 
involvement in induction of apoptosis by VC-A, we evaluated 
Figure 1. Verrucarin A inhibits proliferation of PDA cells. MiaPaCa-2, Panc-1 and BxPC-3 cells (1x104/well) were seeded in a 96-well plate for 24 h. Cells 
were then treated with VC-A at concentrations ranging from 0 to 0.625 µM for 72 h in triplicate. Cell viability was measured by MTS assay using CellTiter 
AQueous assay system. *p<0.05 compared to control cells. Experiment was repeated three times.
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mitochondrial depolarization in cells treated with VC-A. 
Thus, MiaPaCa-2 and BxPC-3 cells were treated with VC-A 
(0-0.625 µM) for 24 h and then loaded with mitochondrial-
potential sensor probe JC-1 and fluorescence emission was 
analyzed by flow cytometry. There was significant change in 
the mitochondrial potential in both cell lines after treatment 
with VC-A. As shown in Fig. 4A, the percentage of MiaPaCa-2 
cells with green fluorescence significantly increased from 3% 
at 0 µM VC-A to 29, 42, 44 and 48% at 0.078-0.625 µM VC-A 
(p<0.01). VC-A also showed strong mitochondrial depolar-
izing effect on BxPC-3 cells (e.g., 5, 39, 53, 66 and 62% of cells 
with green fluorescence at 0, 0.078, 0.156, 0.312 and 0.625 µM 
VC-A, p<0.01).
We also analyzed the effect of VC-A on the release of 
cytochrome c from mitochondria. Western blot analysis 
of mitochondrial fraction of MiaPaCa-2 and BxPC-3 cells 
treated with VC-A (0-0.625 µM) demonstrated the release of 
cytochrome c in both cell lines in a concentration-dependent 
manner (Fig. 4B). Taken together, the loss of mitochondrial 
membrane potential and release of cytochrome c from 
Figure 2. Effect of verrucarin A on cell cycle progression and cell cycle regulatory proteins. (A) Effect on cell cycle progression. MiaPaCa-2 and BxPC-3 
cells were treated with VC-A (0-0.08 µM) for 48 h. Cells were fixed in 70% ethanol and then stained with ethidium bromide. The cell cycle distribution was 
determined by analyzing cellular DNA content by flow cytometry using Accuri 6 flow cytometer (Becton-Dickinson). (B) Effect of cell cycle-regulatory 
proteins. MiaPaCa-2 and BxPC-3 cells were treated with VC-A (0-0.625 µM) for 24 h and cell lysates were analyzed for levels of cyclin D1, cyclin E, cdk2, 
cdk4 and p21 by western blotting. The densitometry analysis of immunoblots was performed using Image/J software and normalized to the corresponding 
β-actin values. Values above blots represent change in protein expression compared to untreated control considered as 1.0. Experiment was repeated two times.
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Figure 3. Verrucarin A induces apoptosis in PDA cells. (A) Annexin V-FITC binding. MiaPaCa-2 and BxPC-3 cells were treated with VC-A (0-0.625 µM) for 
24 h. Cells were then reacted with 5 µl of Annexin V-FITC reagent and 5 µl of PI for 30 min at room temperature. Annexin V-FITC-binding was assessed by 
flow cytometry. Results are presented as percentage of Annexin V-FITC-positive cells ± SD of three separate experiments. *p<0.05 compared to control cells. 
(B) Cleavage of PARP-1. MiaPaCa-2 and BxPC-3 cells were treated with VC-A as in (A) and cell lysates were analyzed for the cleavage of native PARP-1 
by western blotting. Immunoblots show cleaved PARP-1 protein bands (89 kDa). (C) Cleavage of procaspases. Tumor cells were treated with VC-A as in (A) 
and cell lysates were analyzed by immunoblotting for processing of procaspases-3, -8 and -9. The densitometry analysis of immunoblots in (B) and (C) was 
performed using Image/J software and normalized to the corresponding β-actin values. Values above blots represent change in protein expression compared 
to untreated control considered as 1.0. Similar results were obtained in two independent experiments.
Figure 4. VC-A induces mitochondrial depolarization and release of cytochrome c. (A) Mitochondrial depolirazation. MiaPaCa-2 and BxPC-3 cells with VC-A 
(0-0.625 µM for 24 h. Cells were then loaded with mitochondrial sensor dye JC-1 for 10 min and analyzed by flow cytometry. Data shown are percentage of 
cells with mitochondrial depolarization ± SD. Similar results were obtained in two separate experiments. *p<0.05 compared to control cells. (B) Cytochrome c 
release. For cytochrome c release from mitochondria, mitochondrial fractions were prepared from control and treated cells using ApoAlert Cell Fractionation 
kit (Clontech, Laboratories Inc., CA, USA) and cytochrome c analyzed by western blotting. The densitometry analysis of immunoblots was performed using 
Image/J software and normalized to the corresponding Cox-IV values. Values above blots represent change in protein expression compared to untreated control 
considered as 1.0. Similar results were obtained in two independent experiments in (A) and (B).
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mitochondria indicated that mitochondrial damage plays a 
significant role in apoptotic cell death of PDA cells by VC-A.
VC-A does not induce ROS generation. Since generation 
of free radicals is part of the mechanism by which most 
chemotherapeutic agents induce apoptosis in cancer cells 
we evaluated the generation of ROS by VC-A in PDA cells. 
This was accomplished by detecting H2O2 production by flow 
cytometry using H2DCFDA fluorescent probe. As shown in 
Fig. 5, whereas treatment of MiaPaCa-2 and BxPC-3 cells 
with H2O2 resulted in production of hydroxyl radicals (positive 
control) treatment with VC-A at 1.25 and 2.5 µM for 2 h failed 
to induce the generation of these free radicals. Further, no 
ROS was detected either when cells were treated with VC-A 
for 1 or 4 h (not shown).
VC-A downregulates Bcl-2 and IAP family proteins. To further 
characterize apoptotic response of PDA cells to VC-A, the effect 
of VC-A on proteins belonging to the Bcl-2 and IAP families of 
proteins that regulate apoptosis positively and negatively was 
determined. For this, cell lysates prepared from MiaPaCa-2 
and BxPC-3 cells treated or not with VC-A (0.079-0.625 µM) 
for 24 h were analyzed for Bcl-2, Bcl-xL, Bax, p-Bad, survivin 
and c-IAP-2 by western blotting. As shown in Fig. 6, treatment 
with VC-A significantly to completely inhibited the levels of 
antiapoptotic Bcl-2 and Bcl-xL in both cell lines. Proapoptotic 
Bax was unaffected in MiaPaCa-2 cells but was reduced in 
BxPC-3 cells. Even though Bax levels were somewhat reduced 
in BxPC-3 cells but the Bax/Bcl-2 ratio was increased 2-3-fold 
in both cell lines treated with VC-A (e.g., MiaPaCa-2: 2.7-, 2.7-, 
3.2- and 2.7-fold; BxPC-3: 3-, 2-, 3- and 2-fold at 0.079, 0.158, 
0.312 and 0.625 µM, respectively). Proapototic p-Bad was 
also reduced but still detectable in both cell lines. Similarly, 
antiapoptotic survivin (IAP family member) was significantly 
reduced in both cell lines (60-80%). On the other hand, while 
cIAP-2 was markedly reduced at 0.312 and 0.625 µM VC-A in 
MiaPaCa-2 cells, effect on c-IAP-2 expression in BxPC-3 cells 
was minimal. Overall, these data suggested that inhibition of 
antiapoptotic proteins plays a role in induction of apoptosis by 
VC-A in PDA cells.
VC-A inhibits Akt, mTOR and NF-κB signaling proteins and 
their downstream mediators. Akt/NF-κB/mTOR is a major 
antiapoptotic (prosurvival) signaling pathway that confers 
survival advantage in cancer cells including PDA cells. We 
investigated whether induction of apoptosis in prostate cancer 
cells by VC-A involved the inhibition of Akt, mTOR and 
NF-κB and their downstream mediators. Thus, cell lysates 
prepared from MiaPaCa-2 and BxPC-3 cells treated or not 
with VC-A (0-0.625 µM) for 24 h were analyzed for p-Akt, 
mTOR and NF-кB and their effectors by western blotting. 
Treatment with VC-A markedly reduced the levels of p-Akt, 
p-mTOR and NF-кB (p65) in both cell lines (Fig. 7). Further 
analysis of cell lysates showed that VC-A also inhibited 
the major downstream intermediary targets of Akt, mTOR 
and NF-κB. For instance, VC-A inhibited the expression of 
p-Foxo-3α, the downstream target of activated Akt involved in 
cell proliferation and apoptosis. Similarly, the levels of mTOR 
Figure 5. VC-A does not induce ROS generation in PDA cells. Subconfluent cultures of MiaPaCa-2 and BxPC-3 cells were treated with VC-A (1.25 or 2.5 µM) 
or H2O2 (100 µM) for 2 h. Cells were then reacted with 5 µM H2DCFDA for 30 min at 37˚C and DCF fluorescence was measured by flow cytometry. In 
contrast to PDA cells treated with H2O2 (positive control), none to barely detectable DCF fluorescence was detected in cells treated with VC-A. Experiment 
was repeated two times.
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effectors such as p-S6K1 (p-70S6 kinase) and p-eIF-4e were 
markedly decreased after treatment with VC-A. In addition, 
the levels of angiogenesis related Cox-2 and VEGF, which 
are transcriptionally regulated by NF-κB were also markedly 
reduced. Collectively, these data suggested that the inhibition 
of p-Akt, p-mTOR, NF-κB and their downstream mediators 
might be necessary for induction of apoptosis in PDA tumors 
by VC-A.
Discussion
There is an urgent need for effective and safe novel agents 
with defined therapeutic targets for treating pancreatic cancer. 
Natural products have long been recognized as a rich source 
of chemical diversity and compounds with a wide spectrum 
of anticancer activities (22,23). Indeed, isolation and identi-
fication of bioactive components from medicinal plants have 
Figure 6. Effect of VC-A on apoptosis-regulating proteins. MiaPaCa-2 and BxPC-3 cells were treated with VC-A at 0-0.065 µM for 24 h and cell lysates were 
analyzed for Bcl-2, Bcl-xL, Bax, p-Bad, survivin and c-IAP-2 by western blotting. The densitometry analysis of immunoblots was performed using Image/J 
software and normalized to the corresponding β-actin values. Values above blots represent change in protein expression compared to untreated control 
considered as 1.0. Experiment was repeated two times.
Figure 7. VC-A inhibits prosurvival p-Akt, NF-κB and p-mTOR. MiaPaCa-2 and BxPC-3 cells were treated with VC-A at 0-0.625 µM for 24 h and cell lysates 
were analyzed for p-Akt, NF-κB, p-mTOR and their downstream mediators (p-Foxo3α, Cox-2, VEGF, p-70S6, and p-eIF-4e, etc.) or β-actin (loading control) 
by western blotting. The densitometry analysis of immunoblots was performed using Image/J software and normalized to the corresponding β-actin values. 
Values above blots represent change in protein expression compared to untreated control considered as 1.0. Experiment was repeated two times.
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led to the synthesis of potent anticancer drugs, including 
Vinca alkaloids, taxol, camptothecan, etoposide and retinoids. 
Verrucarin A (VC-A) is a macrocyclic trichothecene myco-
toxin that has shown strong antiproliferative and proapoptotic 
activity in breast cancer cells (17,18), providing some insights 
into the mode of action of VC-A. However, the antitumor 
activity or the mechanism of action of VC-A in pancreatic 
cancer cells has not been investigated. Thus, this study was 
undertaken to investigate the antitumor activity and to identify 
targets of VC-A in PDA cells. VC-A inhibited the proliferation 
of three PDA cell lines (e.g., MiaCa-2, Panc1 and BxPC-3) at 
very low concentrations. The antiproliferative effect of VC-A 
was attributed to the inhibition of cell cycle progression in S 
phase. This finding however differs from a previous report 
in which VC-A was shown to arrest cells in G0/G1 phase 
(17). Furthermore, cell cycle arrest by VC-A was associated 
with the inhibition of cyclin D1, cyclin E, cdk2, cdk-4 and 
cdk inhibitor p21. Cyclin D and E in conjunction with cdk2, 
cdk4 and cdk6 regulate cell cycle progression through G1 and 
S phases. The inhibition of cyclin E and cdk2 suggests that 
inhibition of these proteins would result in decreased forma-
tion of cyclin E-cdk2 complexes and therefore accumulation 
of cells in S phase. The cip/kip family member p21 halts cell 
cycle progression by inhibiting cyclin-cdk complexes. VC-A 
only partially reduced p21 in PDA cells, perhaps not enough to 
hamper the activity of cyclin E-cdk2 complexes.
The inability to induce apoptosis has been implicated in 
cancer development and resistance to cancer therapies (24). On 
the other hand, promotion of apoptosis in cancer cells could 
potentially lead to tumor regression and improved prognosis 
(25). The inhibition of cell proliferation by anticancer agents 
normally forces tumor cells to undergo apoptosis. Indeed, 
VC-A induced apoptosis in PDA cells as demonstrated by the 
increased binding of Annexin V and cleavage of PARP-1 and 
procaspases-3, -8 and -9. These results corroborate the find-
ings of another study that also reported cell cycle arrest and 
induction of apoptosis in breast cancer cells by VC-A (17). The 
cleavage of procaspases-8 and -9 suggested that VC-A induces 
both the extrinsic and intrinsic pathways of apoptosis. However, 
additional studies, such as an increase in the expression of death 
receptors DR4 and DR5, are required to confirm the activation 
of extrinsic pathway of apoptosis by VC-A. Mitochondria plays 
a critical role in the intrinsic pathway of apoptosis. Breakdown 
in mitochondrial integrity and the release of cytochrome c and 
other apoptogenic mediators are the best indicators of apoptotic 
cell death via the intrinsic pathway of apoptosis. VC-A induced 
mitochondrial depolarization and release of cytochrome c indi-
cating the involvement of mitochondrial or intrinsic pathway of 
apoptosis in death of PDA cells by VC-A.
The generation of free radicals facilitates cancer cell 
death by most chemotherapeutic agents and ionizing radiation 
(26,27). Our findings demonstrated that production of hydrogen 
peroxide is not involved in death of PDA cells by VC-A. This 
finding contradicts a previous report in which ROS was shown 
to be involved in killing of breast cancer by VC-A (17). Our 
results, however, do not rule out participation of other reactive 
oxygen species such as superoxide anion in VC-A induced death 
of PDA cells.
Apoptosis is regulated by members of the Bcl-2 family of 
proteins that includes both pro- and anti-apoptotic molecules 
(28,29). Members of the IAP family are also potent inhibitors 
of apoptosis (30). Bcl-2 and Bcl-xL are two major antiapop-
totic Bcl-2 family members that reside in the mitochondrial 
membrane and inhibit apoptosis by preventing the activation of 
inner mitochondrial permeability transition pore and release of 
proapoptogenic mitochondrial contents including cytochrome c 
(29). VC-A inhibited Bcl-2 and Bcl-xL in PDA cells. Bax and 
p-Bad which counteract antiapoptotic Bcl-2 and Bcl-xL were 
either not affected or only partially reduced by VC-A. Since both 
anti- and proapoptotic Bcl-2 family members were inhibited or 
reduced the exact nature of the interplay between antiapoptotic 
and proapoptotic members of Bcl-2 family in induction of 
apoptosis in PDA cells by VC-A remains unresolved. On the 
contrary, however, increase in Bax:Bcl-2 ratio after treatment 
with VC-A suggests that VC-A may exert proapoptotic effect 
by displacing Bcl-2 from mitochondria through Bax.
Prosurvival phosphatidylinositol-3 kinase/Akt/NF-кB/
mTOR (PI3K/Akt/NF-кB/mTOR) is a major signaling axis 
which controls cell proliferation, survival, apoptosis, and 
malignant transformation (31). PI3K/Akt signaling is frequently 
activated in a variety of malignancies (32). p-Akt promotes cell 
growth and survival by inactivating downstream substrates 
such as Bad, procaspase-9, and Forkhead transcription factors 
(33,34). Antiapoptotic NF-κB and progrowth mTOR signaling 
pathways are downstream targets of activated Akt. NF-κB 
family of transcription factors controls the expression of genes 
involved in immune and inflammatory responses, cell prolif-
eration, oncogenesis, angiogenesis, and several Bcl-2 family 
members (35). NF-κB also plays a critical role in resistance 
of cancer cells to anticancer therapies by protecting them 
from apoptosis. mTOR, a 290-kDa serine-threonine kinase, 
which controls cell growth, survival and division is activated 
in a variety of human tumors (36). Our results demonstrated 
that Akt, NF-κB and mTOR are constitutively active in PDA 
cells and their expression was inhibited by VC-A. VC-A also 
reduced the expression of several downstream effectors of Akt, 
NF-κB and mTOR that regulate cell proliferation, cell cycle, 
apoptosis and ribogenesis. These findings suggest that the 
inhibition of Akt/NF-кB/mTOR signal transduction pathway 
plays a critical role in induction of apoptosis in pancreatic 
cancer cells by VC-A.
Collectively, results of this study indicate that VC-A is a 
promising agent worthy of further development for the treat-
ment of pancreatic cancer.
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